Skip to main content
main-content

Nephropathy

News

20-09-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

09-09-2019 | Nephropathy | News

Meta-analysis supports use of SGLT2 inhibitors to prevent kidney failure

Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.

03-09-2019 | Retinopathy | News

Microvascular benefits of lowest HbA1c target in type 1 diabetes questioned

Aiming for the lowest international targets in glycated hemoglobin levels may not protect against retinopathy and nephropathy in patients with type 1 diabetes, research suggests.

Read more

Opinion

06-08-2019 | SGLT2 inhibitors | Editorial | Article

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

08-05-2017 | Metformin | Editorial | Article

Metformin: What is new with this old medication?

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.

04-11-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

Journal articles and book chapters

08-11-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

08-09-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

15-08-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

Case reports

Image Credits